On the other hand, increased expressions of PARP1 and POLD2 (DNA polymerase delta subunit 2) are associated with worse outcomes in MM, suggesting that targeting the BER pathway might improve treatment effectiveness [35,36,37]. The gene discussed is POLD2; the disease is Miyoshi myopathy.